Jaquelin Lira

Dr. Jaquelin Lira

UNAM
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
JRJiram Torres Ruiz
Jiram Torres Ruiz
AAAbdiel Absalón-Aguilar
Abdiel Absalón-Aguilar
MNMiroslava Nuñez-Aguirre
Miroslava Nuñez-Aguirre
APAlfredo Pérez-Fragoso
Alfredo Pérez-Fragoso
DCDaniel Carrillo
Daniel Carrillo
DCDaniel Carrillo
Daniel Carrillo
The coronavirus disease 2019 (COVID-19) is related to enhanced production of NETs, and autoimmune/autoinflammatory phenomena. We evaluated the proportion of low-density granulocytes (LDG) by flow cytometry, and their capacity to produce NETs was compared with that of conventional neutrophils. NETs and their protein cargo were quantified by confocal microscopy and ELISA. Antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA) and the degradation capacity of NETs were addressed in serum. MILLIPLEX assay was used to assess the cytokine levels in macrophages’ supernatant and serum. We found a higher proportion of LDG in severe and critical COVID-19 which correlated with severity and inflammatory markers. Severe/critical COVID-19 patients had higher plasmatic NE, LL-37 and HMGB1-DNA complexes, whilst ISG-15-DNA complexes were lower in severe patients. Sera from severe/critical COVID-19 patients had lower degradation capacity of NETs, which was reverted after adding hrDNase. Anti-NET antibodies were found in COVID-19, which correlated with ANA and ANCA positivity. NET stimuli enhanced the secretion of cytokines in macrophages. This study unveils the role of COVID-19 NETs as inducers of pro-inflammatory and autoimmune responses. The deficient degradation capacity of NETs may contribute to the accumulation of these structures and anti-NET antibodies are related to the presence of autoantibodies.

Verified
Journal Article
Open access
PDF file
KSKarina Santana
Karina Santana
JTJiram Torres-Ruiz
Jiram Torres-Ruiz
NMNancy R. Mejía-Domínguez
Nancy R. Mejía-Domínguez
BABeatriz Alcalá-Carmona
Beatriz Alcalá-Carmona
JMJOSE LUIS MARAVILLAS-MONTERO
JOSE LUIS MARAVILLAS-MONTERO
DCDaniel Carrillo
Daniel Carrillo
The coronavirus disease 2019 (COVID-19) survivors are frequently observed to present persistent symptoms constituting what has been called “post-acute COVID-19 syndrome” (PACS) or “long COVID-19”. Some clinical risk factors have been identified to be associated with PACS development; however, specific mechanisms responsible for PACS pathology remain unknown. This study investigates clinical, immunological, and metabolomic risk factors associated with post-acute COVID-19 syndrome (PACS) in 51 patients, assessed 7–19 months after acute infection. Among the participants, 62.7% were male and 37.2% were female, with an average age of 47.8 years. At the follow-up, 37.2% met the criteria for PACS, revealing significant differences in immunological and metabolomic profiles at the time of acute infection. Patients with PACS were characterized by elevated levels of mature low-density granulocytes (LDGs), interleukin-8 (IL-8), pyruvate, pseudouridine, and cystine. Baseline multivariate analysis showed increased pyruvate and decreased alpha tocopherol levels. At follow-up, there was a decrease in absolute B lymphocytes and an increase in non-classical monocytes and 3-hydroxyisovaleric acid levels. These findings suggest that specific immunological and metabolomic markers during acute infection can help identify patients at higher risk of developing persistent PACS.

24 November 2021 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
JRJiram Torres Ruiz
Jiram Torres Ruiz
JLJulieta Lomelín‐Gascón
Julieta Lomelín‐Gascón
Jaquelin LiraJaquelin Lira
Jaquelin Lira
APAlfredo Pérez‐Fragoso
Alfredo Pérez‐Fragoso
RTRoberto Tapia-Conyer
Roberto Tapia-Conyer
DCDaniel Carrillo
Daniel Carrillo
Click on the article title to read more.